Stockscreener 앱 받기
19.04
1.91%
-0.32
전일 마감가:
$19.36
열려 있는:
$19.01
하루 거래량:
54,492
Relative Volume:
0.25
시가총액:
$346.80M
수익:
$116.88M
순이익/손실:
$-25.09M
주가수익비율:
-136.00
EPS:
-0.14
순현금흐름:
$-20.74M
1주 성능:
-2.16%
1개월 성능:
+10.15%
6개월 성능:
+30.97%
1년 성능:
+58.25%
1일 변동 폭
$18.70
$19.45
1주일 범위
$18.64
$19.86
52주 변동 폭
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
명칭
Rigel Pharmaceuticals
전화
650-624-1100
주소
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
18.98 | 346.80M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.70 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.18 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.39 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.38 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.48 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-03 | 재개 | Piper Sandler | Neutral |
| 2022-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-08 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 개시 | B. Riley Securities | Neutral |
| 2020-11-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 재개 | JP Morgan | Overweight |
| 2019-03-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 개시 | Citigroup | Buy |
| 2018-05-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 재개 | Piper Jaffray | Overweight |
| 2017-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 재개 | H.C. Wainwright | Buy |
| 2017-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-31 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 재확인 | Piper Jaffray | Overweight |
| 2016-07-13 | 개시 | H.C. Wainwright | Buy |
| 2016-06-13 | 개시 | Piper Jaffray | Overweight |
| 2016-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 재확인 | Stifel | Buy |
| 2012-11-29 | 개시 | UBS | Neutral |
| 2012-11-06 | 재확인 | Oppenheimer | Outperform |
| 2012-03-26 | 개시 | Canaccord Genuity | Hold |
| 2010-12-10 | 다운그레이드 | MP Advisors | Outperform → Market Perform |
모두보기
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update - Kilgore News Herald
Rigel Announces Conference Call and Webcast to Report First Quar - GuruFocus
Rigel Pharmaceuticals Sets Key Q1 2025 Earnings Date: How to Access Latest Biotech Results - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
(RIGL) Trading Report - news.stocktradersdaily.com
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Stocks That Fell to 3-Year Lows in the Week of Sept. 13 - GuruFocus
Where are the Opportunities in (RIGL) - news.stocktradersdaily.com
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
High Growth Tech Stocks in the US for April 2025 - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PR Newswire
Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - Stock Titan
(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (RIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):